Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
Endocrinology Department & Lab of Endocrine and Metabolic Research, IRCCS-Istituto Auxologico Italiano, Milan, Italy.
Front Endocrinol (Lausanne). 2023 Jun 6;14:1179817. doi: 10.3389/fendo.2023.1179817. eCollection 2023.
The follow-up strategy for unresected non-functional adrenal tumors (NFAT) is a major controversial issue in endocrinological clinical practice, as the natural history of adrenal incidentalomas (AI) is partially unknown and a consensus on their adequate management is lacking. In a recent longitudinal study by Ceccato et al., a large cohort of patients with conservatively treated AI were evaluated for possible radiological variations over time and their relationship with autonomous cortisol secretion (ACS). Starting from this paper, we performed a literature review of available longitudinal studies focus on the same issue. Notwithstanding the high variability in the duration of follow-up and in the criteria used to define ACS in the included studies, our findings support the idea that there is a not negligible risk of morphological and functional changes, which may have metabolic implications, especially after 5-10 years of follow-up. Unfortunately, these variations seem to be scarcely predictable. Therefore, it may be risky to interrupt the follow-up in patients with NFAT, in particular in the presence of larger diameter of the adenoma and higher cortisol levels at diagnosis. These results should be considered in defining the optimal management of these patients.
未切除的无功能性肾上腺肿瘤(NFAT)的随访策略是内分泌临床实践中的一个主要争议问题,因为肾上腺意外瘤(AI)的自然史部分未知,并且缺乏对其适当管理的共识。在 Ceccato 等人最近的一项纵向研究中,对接受保守治疗的 AI 患者进行了评估,以观察其在一段时间内可能出现的影像学变化及其与自主皮质醇分泌(ACS)的关系。从这篇论文出发,我们对关于同一问题的现有纵向研究进行了文献回顾。尽管纳入研究的随访时间和用于定义 ACS 的标准存在高度变异性,但我们的研究结果支持这样一种观点,即存在形态和功能变化的不可忽视的风险,尤其是在随访 5-10 年后。不幸的是,这些变化似乎难以预测。因此,在 NFAT 患者中中断随访可能存在风险,特别是在腺瘤直径较大和诊断时皮质醇水平较高的情况下。这些结果应在确定这些患者的最佳治疗方案时加以考虑。